JNM Podcast

Get ready for an episode that's a bit...meta. In Episode 7, our host Ken Herrmann is joined by the podcasters behind GU Cast: Declan Murphy, FRACS, FRCS, and Renu Eapen, MBBS, FRACS. Together with Wolfgang Weber, MD, PhD, they discuss how social media has shaped the landscape of medicine - from how we get medical news, to sharing new research to interacting with colleagues and patients. Tune...

Join us for episode 6 of the JNM podcast. Moderator Ken Herrmann, MD is joined by Simron Singh, MD and Lisa Bodei, MD, PhD to discuss NETTER-2. NETTER-2 was the first trial to examine radioligand therapy as a first-line therapy for cancers, as opposed to waiting until later stages. Our panelists discuss the results of this trial and its implications for patients. Thank you to SOFIE Biosciences for...

Radioligand therapy (RLT) targets cancer cells with radiation while minimizing impact on surrounding healthy tissue. In this episode of JNM Podcast, our panelists discuss training, access, production capacity, and everything else that is necessary to make RLT more widely available to the patients who need it. Moderator: Ken Herrmann, MD (Universitätsmedizin, Essen, Germany).  Panelists: Andrei Iag...

The VISION Trial is the first-in-its-field study to use radiopharmaceuticals that directly target prostate cancer tumors. Hear from one of the lead researchers on this ground-breaking study as he discusses how the trial has opened up a completely new field of study in prostate cancer research and shaped the future of nuclear medicine therapy in combatting the disease. Join us for Episode 4 of JNM...

The Journal of Nuclear Medicine presents a new podcast on advances in dementia imaging. Panelists discuss the importance of amyloid and tau PET imaging in dementia diagnosis and treatment, highlighting their roles in clinical trials and future therapies. They emphasize the significance of early detection and the potential for personalized medicine approaches. Panel:  • Ken Herrmann, MD, MBA (Unive...

This month's episode of the JNM Podcast takes the discussion of Pb-212 worldwide! Researchers from the UK, Australia, and North America discuss the logistics of using lead-212 as a radionuclide imaging agent. From availability to production to transportation, Pb-212 presents both great opportunities and great challenges. Moderator Ken Herrmann, MD, leads this intercontinental panel in a discu...

The Journal of Nuclear Medicine presents a new podcast on FAPI-directed theranostics for cancer diagnosis and treatment. Join moderator Ken Herrmann (Universitätsmedizin) and panelists Andrew Scott (Austin Health), Katharina Lückerath (Universitätsmedizin) and Shadi Esfahadi (Mass General Hospital) as they delve into the history of FAP, discuss challenges, and predict the pathway to clinical succe...